The First Industry Led COPD Drug Development Conference
COPD drug development has entered a new phase of momentum. After decades of stalled progress, recent scientific advances, including the approval of the first biologic therapy have reshaped what is possible in the COPD landscape. This shift has repositioned COPD as a credible and compelling frontier for innovation and investment, demanding a dedicated, industry‑driven forum to chart the path forward.
The COPD Drug Development Summit is the first conference built by and for industry experts, designed to address the biological, clinical, and commercial challenges that have historically limited success in the field. The agenda focuses on how to capitalise on this renewed opportunity, spanning novel targets and modalities, translational insights, smarter trial design, emerging endpoints, and regulatory strategy.
Join top leaders from biotech and pharma to share lessons and shape the next chapter of innovation. This is a focused forum to build partnerships, reduce development risk, and translate renewed momentum into disease‑modifying therapies to solve a huge unmet need.
Join the Industry Forum Tackling COPD’s Shared Development Challenges
COPD Trials Rely on Endpoints That Don’t Show True Clinical Value
Debate reliance on exacerbations and FEV₁, exploring alternative endpoints that better reflect patient benefit, disease progression, and treatment impact, while addressing how to gain regulatory confidence when proposing novel measures.
Heterogenous Patient Populations Lead to Challenging Trial Design
Discover how endotype‑driven patient segmentation can improve treatment selection, reduce trial size and duration, and increase the likelihood of detecting true therapeutic response beyond broad clinical categories.
Preclinical Models Don’t Predict What Happens in the Clinic
Examine why traditional models fall short and how human‑relevant data, advanced systems, and emerging technologies can better align preclinical findings with clinical biology, reducing translational risk and late‑stage failure.
We Lack Objective Tools to Detect Progression and Prove Early Benefit
Learn how advanced imaging and AI can deliver sensitive, reproducible measures of disease progression, target engagement, and early efficacy, supporting earlier decisions, stronger proof‑of‑concept, and next‑generation endpoints.
Explore the Full Event Guide
- Network with 65+ discovery, translational, clinical and regulatory experts from the likes of Johnson & Johnson, Sanofi, GSK, AstraZeneca, Merck, Connect Biopharma, Generate Biomedicines, Ethris, and many more
- Critical debates on regulatory expectations and opportunities to validate novel endpoints that de‑risk development and support faster, more confident approvals
- Expert perspectives on combining imaging, molecular, and clinical data to build a more holistic view of COPD biology and improve translational success
- Hear from 16+ respiratory specialists and C-level executives presenting novel targets and clinical trial strategies
- 3 days of essential industry collaboration including over 6 hours of specialized networking
Attending Companies Include
Explore the Brand-New Agenda
Hear fresh industry perspectives, strategic case studies, and candid discussions tackling the biggest scientific and commercial questions shaping COPD R&D today.
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is at the forefront of this resurging market.
Join An Intimate Community of Experts
Join a highly selective group of experts across discovery, translational, clinical, and regulatory development to exchange insights and build meaningful, high‑impact connections.